Use of a Web-based App to Improve Breast Cancer Symptom Management and Adherence for Aromatase Inhibitors: a Randomized Controlled Feasibility Trial

Overview

Journal J Cancer Surviv

Specialty Oncology

Date 2018 Mar 2

PMID 29492753

Citations 50

Authors

Ilana Graetz

Caitlin N McKillop

Edward Stepanski

Gregory A Vidal

Janeane N Anderson

Lee S Schwartzberg

Affiliations

Soon will be listed here.

Abstract

Purpose: For postmenopausal women with hormone receptor-positive breast cancer, long-term use of aromatase inhibitors (AIs) significantly reduces the risk of cancer recurrence and improves survival. Still, many patients are nonadherent due to adverse side effects. We conducted a pilot randomized controlled trial to test the use of a web-based application (app) designed with and without weekly reminders for patients to report real-time symptoms and AI use outside of clinic visits with built-in alerts to patients' oncology providers. Our goal was to improve symptom burden and medication adherence.

Methods: Forty-four women with early-stage breast cancer and a new AI prescription were randomized to either an App+Reminder (weekly reminders to use app) or an App (no reminders) group. Pre- and post-assessment data were collected from all participants.

Results: Participants in the App+Reminder group had higher weekly app usage rate (74 vs. 38%, p < 0.05) during the intervention and reported higher AI adherence at 8 weeks (100 vs. 72%, p < 0.05). Symptom burden increase was higher for the App group compared to the App+Reminder group but did not reach statistical significance.

Conclusions: Weekly reminders to use a web-based app to report AI adherence and treatment-related symptoms demonstrated feasibility and improved short-term AI adherence, which may reduce symptom burden for women with breast cancer and a new AI prescription.

Implications For Cancer Survivors: If short-term gains in adherence persist, this low-cost intervention could improve survival outcomes for women with breast cancer. A larger, long-term study should examine if AI adherence and symptom burden improvements persist for a 5-year treatment period.

Citing Articles

Development and evaluation of a WeChat-based intervention program for prevention of breast cancer-related lymphedema.

Luo X, He H, Chen J, Li M, Yan J Support Care Cancer. 2024; 33(1):19.

PMID: 39663241 DOI: 10.1007/s00520-024-09078-x.

Factors Associated With Digital Intervention Engagement and Adherence in Patients With Cancer: Systematic Review.

Montalescot L, Baussard L, Charbonnier E J Med Internet Res. 2024; 26:e52542.

PMID: 39661976 PMC: 11669875. DOI: 10.2196/52542.

Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy.

Krukowski R, Hu X, Arshad S, Anderson J, Stepanski E, Vidal G JCO Clin Cancer Inform. 2024; 8:e2400179.

PMID: 39642329 PMC: 11631045. DOI: 10.1200/CCI-24-00179.

Effectiveness of ePRO-based symptom management for cancer patients: a systematic review and meta-analysis of randomized controlled studies.

Hang L, Zhang J, Lu Z, Xu J, Chen Y Support Care Cancer. 2024; 32(12):842.

PMID: 39621108 DOI: 10.1007/s00520-024-09026-9.

Current status and hotspots in breast cancer patient self-management research: A bibliometric and visual analysis via CiteSpace.

Chen X, Cao Y, Huang S, Chen Y, Zhang C Medicine (Baltimore). 2024; 103(46):e39945.

PMID: 39560549 PMC: 11575949. DOI: 10.1097/MD.0000000000039945.

References

Fortner B, Okon T, Schwartzberg L, Tauer K, Houts A . The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. J Pain Symptom Manage. 2003; 26(6):1077-92. DOI: 10.1016/j.jpainsymman.2003.04.003. View

Kyvernitakis I, Ziller V, Hars O, Bauer M, Kalder M, Hadji P . Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric. 2013; 17(3):252-9. DOI: 10.3109/13697137.2013.819327. View

Hershman D, Tsui J, Wright J, Coromilas E, Tsai W, Neugut A . Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol. 2015; 33(9):1053-9. PMC: 4356713. DOI: 10.1200/JCO.2014.58.3062. View

Chew L, Bradley K, Boyko E . Brief questions to identify patients with inadequate health literacy. Fam Med. 2004; 36(8):588-94. View

Brier M, Chambless D, Gross R, Chen J, Mao J . Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors. Cancer. 2016; 123(1):169-176. PMC: 5161545. DOI: 10.1002/cncr.30318. View

DeSantis C, Fedewa S, Sauer A, Kramer J, Smith R, Jemal A . Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2015; 66(1):31-42. DOI: 10.3322/caac.21320. View

Simon R, Latreille J, Matte C, Desjardins P, Bergeron E . Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Can J Surg. 2014; 57(1):26-32. PMC: 3908992. DOI: 10.1503/cjs.006211. View

Yu K, Zhou Y, Liu G, Li B, He P, Zhang H . A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer. Breast Cancer Res Treat. 2012; 134(1):307-13. DOI: 10.1007/s10549-012-2059-8. View

Franklin J, Krumme A, Shrank W, Matlin O, Brennan T, Choudhry N . Predicting adherence trajectory using initial patterns of medication filling. Am J Manag Care. 2015; 21(9):e537-44. View

10.

Hunt B, Whitman S, Hurlbert M . Increasing Black:White disparities in breast cancer mortality in the 50 largest cities in the United States. Cancer Epidemiol. 2014; 38(2):118-23. DOI: 10.1016/j.canep.2013.09.009. View

11.

Kadakia K, Snyder C, Kidwell K, Seewald N, Flockhart D, Skaar T . Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist. 2016; 21(5):539-46. PMC: 4861358. DOI: 10.1634/theoncologist.2015-0349. View

12.

Hadji P, Blettner M, Harbeck N, Jackisch C, Luck H, Windemuth-Kieselbach C . The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast.... Ann Oncol. 2013; 24(6):1505-12. DOI: 10.1093/annonc/mds653. View

13.

Bickell N, Wang J, Oluwole S, Schrag D, Godfrey H, Hiotis K . Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006; 24(9):1357-62. DOI: 10.1200/JCO.2005.04.5799. View

14.

Waterhouse D, Calzone K, Mele C, Brenner D . Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993; 11(6):1189-97. DOI: 10.1200/JCO.1993.11.6.1189. View

15.

Sedjo R, Devine S . Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat. 2010; 125(1):191-200. DOI: 10.1007/s10549-010-0952-6. View

16.

Lee H, Koopmeiners J, Rhee T, Raveis V, Ahluwalia J . Mobile phone text messaging intervention for cervical cancer screening: changes in knowledge and behavior pre-post intervention. J Med Internet Res. 2014; 16(8):e196. PMC: 4180333. DOI: 10.2196/jmir.3576. View

17.

Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L . The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE).... Breast. 2014; 23(4):393-9. DOI: 10.1016/j.breast.2014.02.009. View

18.

Hashem M, Cleary K, Fishman D, Nichols L, Khalid M . Effect of concurrent prescription antiarthralgia pharmacotherapy on persistence to aromatase inhibitors in treatment-naive postmenopausal females. Ann Pharmacother. 2013; 47(1):29-34. DOI: 10.1345/aph.1R369. View

19.

Kimmick G, Edmond S, Bosworth H, Peppercorn J, Marcom P, Blackwell K . Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. Breast. 2015; 24(5):630-6. PMC: 4824055. DOI: 10.1016/j.breast.2015.06.010. View

20.

Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H . Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study. Breast Cancer Res Treat. 2012; 133(1):367-73. DOI: 10.1007/s10549-012-1961-4. View